Quest Diagnostics Incorporated Price, Chart & Factor Exposure
Free Data & Analytics AccessLatest earnings: October 22, 2026 results vs estimates
Quest Diagnostics Incorporated Forecast
Quest Diagnostics Incorporated short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 20.1% a year, a typical one-standard-deviation range is 245.75–260.09 over a week, 238.23–267.61 over a month and 202.02–303.82 over a year. (Signals as of 1 Nov 2026.)
Quest Diagnostics Incorporated Price Chart
Quest Diagnostics Incorporated Factors
YoY +12.5%
YoY +20.1%
YoY +24.7%
YoY +13.9%
YoY +12.4%
YoY −24.7%
YoY −11.1%
YoY −18.9%
YoY +31.1%
YoY −7.8%
YoY −14.4%
YoY +50.7%
YoY +51.9%
YoY +20.9%
YoY −6.3%
YoY 0.0%
YoY +14.6%
Quest Diagnostics Incorporated fundamentals: income statement, balance sheet & cash flow
Quest Diagnostics Incorporated reported revenue of $11.04bn and net income of $992.0m in FY2025, the year ended 31 December 2025 — revenue up 11.8% and net income up 13.9% on the prior year. Free cash flow was $1.36bn. These figures are as reported in the filings, not restated: 30 fiscal years and 121 quarters of history, back to December 1996. 173 FINRA short-interest settlements are published alongside them, back to June 2019.
| USD billions | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | 31 Dec 2025 | 31 Dec 2024 | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 |
| Revenue | 11.04 | 9.87 | 9.25 | 9.88 | 10.79 |
| Cost of revenue | 7.37 | 6.63 | 6.20 | 6.45 | 6.58 |
| Gross profit | 3.67 | 3.24 | 3.05 | 3.43 | 4.21 |
| Selling, general & admin. | 1.97 | 1.77 | 1.80 | 1.82 | 1.73 |
| Operating income | 1.56 | 1.35 | 1.26 | 1.43 | 2.38 |
| EBITDA | 2.19 | 1.89 | 1.26 | 1.82 | 3.16 |
| Interest expense | 0.28 | 0.23 | 0.15 | 0.15 | 0.15 |
| Pre-tax income | 1.36 | 1.19 | 1.13 | 1.28 | 2.68 |
| Income tax | 0.31 | 0.27 | -0.25 | 0.26 | 0.60 |
| Net income | 0.99 | 0.87 | 0.85 | 0.95 | 2.00 |
Download Quest Diagnostics Incorporated fundamentals
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.DGX.NYSE&statement=all&freq=a&format=csv&years=10
Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.
Research on Quest Diagnostics Incorporated
Explore MacroFinance macro & markets research and analysis.
Quest Diagnostics Incorporated Trading Strategies
58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Quest Diagnostics Incorporated; 28 of them are invested now. Strategies currently invested are listed first.
| Strategy | Style | Rebalance | Now in SPY, XLV | CAGR | Sharpe | Max DD |
|---|---|---|---|---|---|---|
| Tactical Permanent Portfolio | Conservative | Monthly | Premium · upgrade to view | |||
| Zakamulin and Giner's Optimal Trend Following | Moderate | Monthly | Premium · upgrade to view | |||
| Movement Capital's Composite Strategy | Moderate | Monthly | Premium · upgrade to view | |||
| Harry Browne's Permanent Portfolio | Conservative | Monthly | 25% | 7.0% | 0.96 | -17.2% |
| Keller and Van Putten's Flexible Asset Allocation | Moderate | Monthly | Premium · upgrade to view | |||
| Ned Davis' Three Way Model | Moderate | Monthly | Premium · upgrade to view | |||
| 60_40 Benchmark | Moderate | Monthly | 60% | 8.2% | 0.93 | -29.5% |
| Dick Stoken's Active Combined Asset (ACA) - Monthly Trading | Moderate | Monthly | Premium · upgrade to view | |||
| PortfolioCharts' Golden Butterfly | Moderate | Monthly | 20% | 7.4% | 0.91 | -18.0% |
| US Cross-Asset Momentum | Moderate | Monthly | Premium · upgrade to view | |||
Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.
From creators
- P4 Demo Momentum by admin
- strategyx by admin
Statistical Distribution of Returns
PlusHow Quest Diagnostics Incorporated’s returns are distributed — and how they change in a given market regime.
Regime filters
| Market/Macro | Indicator | Criteria | Value | And (for Between) | Action |
|---|
No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.
| Statistic | All periods | Matching |
|---|
About Quest Diagnostics Incorporated (United States)
Quest Diagnostics Incorporated is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).
Last updated: November 22, 2026
More on Digi Power X Inc.
Frequently asked questions
What is Quest Diagnostics Incorporated?
What is the latest Quest Diagnostics Incorporated price?
Is Quest Diagnostics Incorporated in an uptrend?
How volatile is Quest Diagnostics Incorporated?
What factors affect Quest Diagnostics Incorporated?
Which trading strategies trade Quest Diagnostics Incorporated?
How are Quest Diagnostics Incorporated returns analysed?
Where can I download free Quest Diagnostics Incorporated historical data?
Free Quest Diagnostics Incorporated historical data (last 10 years)
Browse or instantly download the last 10 years of Quest Diagnostics Incorporated daily price history. A free account unlocks the full history, an Excel export with factors, and API access.
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.DGX.NYSE&format=csv&years=10
| Date | Close |
|---|---|
| 2026-11-20 | 258.28 |
| 2026-11-19 | 259.09 |
| 2026-11-18 | 259.69 |
| 2026-11-17 | 256.35 |
| 2026-11-16 | 262.21 |
| 2026-11-13 | 259.6 |
| 2026-11-12 | 259.65 |
| 2026-11-11 | 258.69 |
| 2026-11-10 | 258.44 |
| 2026-11-09 | 259.67 |
About this stock
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer's disease; and women's health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
See how this market's returns behaved when a factor was in a given state, for example when Momentum was strong or bond yields were above 4%, and compare that with all periods.
Reading the chart
- Each bar is a return bucket; its height is the share of periods that landed there.
- All periods: every return in the date range.
- Matching periods: only the periods where all your filters were true. If orange shifts right of the grey, returns were better in that regime.
- Each period's return is the return over the following day, week or month (set by Timeframe), measured from the day the factor was read, so there is no look-ahead.
Adding a filter
- Factor: grouped the same way as the Factors section on this page (Quantitative, Country, Sector, …). Locked factors are listed but greyed out.
- Criteria: greater (>), greater or equal (≥), equal (=), smaller or equal (≤), smaller (<) or between two values.
- Value: depends on the factor.
- Momentum and Trend are signals from −1 to +1, picked as −100 to +100 in steps of 25.
- Mean Reversion is a z-score of price against its 250-day mean, picked in σ from −3 to +3.
- Everything else is a number you type. The line under the box shows the latest reading and its typical range over the last 10 years.
Add several filters to combine conditions; a period must pass every one. Narrow the window with the From/To dates or the 1Y / 5Y / 10Y / MAX buttons; Clear resets filters and dates.
Return statistics
- Unfiltered vs Filtered: all periods vs matching periods.
- Average return, Std dev and Sharpe are annualised (252 days, 52 weeks, 12 months, 6 two-month periods, 4 quarters).
- Maximum drawdown compounds non-overlapping periods; in the Filtered column it assumes you held only while the condition was true.
- Min, 25th percentile, median, 75th percentile and max are per period, not annualised.